

Company registration number 593738 (Republic of Ireland)

**TERSE PHARMA HOLDINGS LIMITED**  
**ABRIDGED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MAY 2025**

# TERSE PHARMA HOLDINGS LIMITED

## CONTENTS

---

	<b>Page</b>
Director's responsibilities statement	1
Statement of financial position	2
Notes to the financial statements	3 - 5

---

# TERSE PHARMA HOLDINGS LIMITED

## DIRECTOR'S RESPONSIBILITIES STATEMENT

**FOR THE YEAR ENDED 31 MAY 2025**

---

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (Generally accepted Accounting Practice in Ireland) issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for that financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On behalf of the board

Terence Simpson  
**Director**

Aisling Nolan  
**Director**

14 November 2025

# TERSE PHARMA HOLDINGS LIMITED

## STATEMENT OF FINANCIAL POSITION

AS AT 31 MAY 2025

	Notes	2025		2024	
		€	€	€	€
<b>Fixed assets</b>					
Financial assets	2		1,713,837		1,713,837
<b>Current assets</b>					
Cash at bank and in hand		41		20	
<b>Creditors: amounts falling due within one year</b>	3	(1,816,892)		(1,816,871)	
<b>Net current liabilities</b>			(1,816,851)		(1,816,851)
<b>Net liabilities</b>			(103,014)		(103,014)
<b>Capital and reserves</b>					
Called up share capital presented as equity			100		100
Profit and loss reserves	4		(103,114)		(103,114)
<b>Total equity</b>			(103,014)		(103,014)

I, as director of Terse Pharma Holdings Limited, state that:

(a) The company is availing itself of the exemption from audit provided for by Chapter 15 of Part 6 of the Companies Act 2014.

(b) The company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied.

(c) The shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2).

(d) The director acknowledges the obligations of the company, under the Companies Act 2014:

(i) to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year; and

(ii) to otherwise comply with the provisions of this Act relating to financial statements so far as they are applicable to the company.

(e) The company has relied on the specified exemption contained in section 352 Companies Act 2014; the company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with Financial Reporting Standard 102 'The Financial Statement Reporting Standard applicable in the UK and Republic of Ireland'.

The financial statements were approved by the board of directors and authorised for issue on 14 November 2025 and are signed on its behalf by:

Terence Simpson  
Director

Aisling Nolan  
Director

# TERSE PHARMA HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

**FOR THE YEAR ENDED 31 MAY 2025**

---

### 1 Accounting policies

#### **Company information**

Terse Pharma Holdings Limited is a limited company domiciled and incorporated in the Republic of Ireland. The registered office is 12 Slade Castle Court, Saggart, Dublin 24 and its company registration number is 593738.

#### 1.1 Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”), as adapted by Section 1A of FRS 102, and the requirements of the Companies Act 2014.

The financial statements are prepared in euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest €.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 1.2 Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

#### 1.3 Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### 1.4 Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company’s statement of financial position when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

#### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

# TERSE PHARMA HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MAY 2025

### 1 Accounting policies

(Continued)

#### **Classification of financial liabilities**

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

#### **Basic financial liabilities**

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

### 1.5 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

### 1.6 Derivatives

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.

A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.

### 2 Financial assets

	2025 €	2024 €
Shares in group undertakings	1,713,837	1,713,837

### 3 Creditors: amounts falling due within one year

	2025 €	2024 €
Amounts due to group undertakings	1,756,942	1,756,921
Other creditors	59,950	59,950
	<u>1,816,892</u>	<u>1,816,871</u>

### 4 Profit and loss reserves

	2025 €	2024 €
Adjusted balance	(103,114)	(103,114)
At the end of the year	<u>(103,114)</u>	<u>(103,114)</u>

# TERSE PHARMA HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MAY 2025

---

### 5 Events after the reporting date

There were no post balance sheet events which require disclosure.

### 6 Related party transactions

ECTA Pharma Holdings Ltd, Terse Pharma Holdings Ltd and Saggart Pharmacy Ltd are group companies.

As at 31st May 2025, there was a balance owed to Saggart Pharmacy Limited from Terse Pharma Holdings Limited of €989,442 (2024: €989,421 ).

As at 31st May 2025, there was a balance owed to ECTA Pharma Holdings Limited from Terse Pharma Holdings Limited of €767,499 (2024: €767,499 ).

### 7 Parent company

Terse Pharma Holdings Limited is a 100% subsidiary of ECTA Pharma Holdings Ltd, ECTA Pharma Holdings Ltd is in turn wholly owned by Terence Simpson.

### 8 Approval of financial statements

The director approved the financial statements on 14 November 2025.